Observational Study of the Use of KRYSTEXXA (Pegloticase)in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy.
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Pegloticase (Primary)
- Indications Gout
- Focus Adverse reactions
- Acronyms EyesOnGOUT
- Sponsors Horizon Pharma; Savient Pharmaceuticals
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2017.